Evidence map›Paper›PMID 42031945›Full record

ArticleScientific reports2026

Differential regulation of immunoglobulin class switch recombination by the tumor suppressor p53.

Kawtar Hanefioui, Audrey Dauba, Charlotte Payrault, Fadila Guessous, Ahmed Amine Khamlichi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kawtar HanefiouiInstitut de Pharmacologie et de Biologie Structurale (IPBS), CNRS UMR5089, Université de Toulouse, 205 Route de Narbonne, BP 64182, 31077, Toulouse, France.
Audrey DaubaInstitut de Pharmacologie et de Biologie Structurale (IPBS), CNRS UMR5089, Université de Toulouse, 205 Route de Narbonne, BP 64182, 31077, Toulouse, France.
Charlotte PayraultInstitut de Pharmacologie et de Biologie Structurale (IPBS), CNRS UMR5089, Université de Toulouse, 205 Route de Narbonne, BP 64182, 31077, Toulouse, France.
Fadila GuessousDepartment of Biomedical Sciences, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca, Morocco.
Ahmed Amine KhamlichiInstitut de Pharmacologie et de Biologie Structurale (IPBS), CNRS UMR5089, Université de Toulouse, 205 Route de Narbonne, BP 64182, 31077, Toulouse, France. ahmed.khamlichi@ipbs.fr.

Funding

Agence Nationale de la Recherche ANR-24-CE15-3761-01, Dev-CSRInstitut National Du Cancer INCA_PLBIO25-074Ligue Contre le Cancer Ligue Régionale: Comités de l'Ex Région Midi-Pyrénées, N°LS 285415
6 · The paper itself

Abstract

Immunoglobulin class switch recombination (CSR) plays an important role in humoral immune response enabling B cells to replace the initial IgM by another antibody class (IgG, IgE or IgA), thus changing the effector functions of antibodies. CSR occurs between highly repetitive switch sequences located upstream of constant gene exons, and is initiated by the Activation-Induced cytidine Deaminase via transcription-dependent deamination of single-stranded DNA targets at switch regions. CSR is preceded by germline transcription and is controlled by the super-enhancer 3' regulatory region (3'RR) in an activation-specific manner. The 3'RR is composed of four enhancers (hs3a, hs1-2, hs3b, and hs4) which act in synergy, and its long-range activity correlates with the enhancers' transcription. In addition to its function as a tumor suppressor, the p53 transcription factor controls various developmental and cellular processes. This multifaceted function is largely due to its context-dependent transcriptional activity, involving both activation and repression of a myriad of target genes. Despite its potential importance for CSR, which implies multiple layers of transcriptional, epigenetic and DNA break/repair regulations, the role of p53 in CSR is still unclear. Here, by using a mouse line devoid of p53, we show that p53 regulates CSR in an isotype-specific manner. Moreover, we provide evidence that p53 has a dual role in the control of germline transcription as it acts both as an activator and a repressor. Finally, we show that p53 is required for hs4 transcription, suggesting a role for p53 in the regulation of the 3'RR's transcriptional activity.

Indexed as

Immunoglobulin Class SwitchingRecombination, GeneticSuper EnhancersTumor Suppressor Protein p53AnimalsB-LymphocytesMiceTranscription, GeneticTumor Suppressor Protein p53Class switch recombinationGermline transcriptionIgH enhancersIgH locusp53

Identifiers

PMID42031945
PMCPMC13280141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.